Daclaxen 60 mg Tablet

Description

Daclaxen 60 mg Tablet contains daclatasvir, an antiviral medicine classified as a direct-acting antiviral (DAA) and NS5A inhibitor. It is used as part of combination therapy for the treatment of chronic hepatitis C virus (HCV) infection in adults. Daclatasvir works by targeting a specific viral protein required for the replication of the hepatitis C virus, helping to reduce the amount of virus in the body when used as prescribed by a qualified healthcare professional. Daclatasvir is typically prescribed together with other antiviral medicines such as sofosbuvir or other approved HCV treatments, depending on the viral genotype, patient condition, and treatment guidelines. Combination therapy is commonly recommended because it improves treatment effectiveness and helps prevent viral resistance. Daclaxen tablets are taken orally and are usually part of a treatment course lasting several wee

Benefits

• Targets the NS5A protein, an essential component of hepatitis C viral replication

• Used in combination antiviral regimens for chronic hepatitis C

• Oral tablet formulation suitable for outpatient treatment

• May help reduce viral load when used as directed by a healthcare professional

• Part of modern direct-acting antiviral therapy for HCV

Indications and Usage

Daclaxen (daclatasvir) may be prescribed for:

• Chronic hepatitis C virus (HCV) infection in adults

• Treatment of certain HCV genotypes when used in combination with other antiviral medicines

• Patients receiving combination antiviral therapy recommended by clinical guidelines

Treatment selection depends on viral genotype, liver condition, and previous treatment history.

How it Works

Daclatasvir works by inhibiting the NS5A protein, a key component required for the hepatitis C virus to replicate and assemble new viral particles. The NS5A protein plays a role in viral RNA replication and the formation of viral replication complexes within infected liver cells.

By blocking this protein, daclatasvir interferes with the virus’s ability to multiply inside the body. When used in combination with other antiviral medicines, this mechanism helps reduce the amount of hepatitis C virus in the bloodstream and may support viral suppression during treatment when taken as prescribed and monitored by a healthcare professional.

Dosage & Administration

• Daclaxen tablets are taken orally with water.

• The medicine may be taken with or without food, unless directed otherwise.

• It is usually prescribed once daily as part of a combination antiviral regimen.

• Tablets should be swallowed whole and not crushed or chewed.

• Treatment duration and dosing schedule are determined by a healthcare professional based on viral genotype, liver condition, and other medications.

Side Effects

Common side effects

• Fatigue

• Headache

• Nausea

• Diarrhea

• Difficulty sleeping (insomnia)

Serious side effects

• Slow heart rate when used with certain medicines such as amiodarone

• Severe liver problems in some patients

• Allergic reactions

• Worsening of hepatitis B infection in patients previously infected

Patients should contact their healthcare provider if severe symptoms occur.

Warning and Precaution

• Risk of serious bradycardia (slow heart rate) when used with amiodarone

• Possible reactivation of hepatitis B virus in previously infected patients

• Liver function should be monitored during treatment

• Inform your healthcare provider about all medicines and supplements you are taking

• Use caution in patients with advanced liver disease

• Pregnancy considerations should be discussed with a healthcare professional

Patient Guidance

• Take the medicine exactly as prescribed by your healthcare provider

• Do not stop treatment early without consulting your doctor

• Attend scheduled laboratory tests and follow-up visits

• Inform your doctor if you have a history of hepatitis B infection

• Avoid missing doses, as this may affect treatment effectiveness

• Store the medicine according to recommended conditions

Clinical Trial & Approvals

Daclatasvir has been evaluated in multiple clinical trials for the treatment of chronic hepatitis C infection across different genotypes. These studies demonstrated that daclatasvir-based combination therapies can achieve high rates of sustained virologic response (SVR) in certain patient groups. Based on clinical evidence, daclatasvir has received approvals in several countries for use in combination therapy for chronic hepatitis C.

References

• U.S. Food and Drug Administration (FDA) – Daclatasvir Drug Information
  https://www.fda.gov

• European Medicines Agency (EMA) – Daclatasvir Product Information
  https://www.ema.europa.eu

• World Health Organization – Hepatitis C Treatment Guidelines
  https://www.who.int

• Drugs.com – Daclatasvir Drug Information
  https://www.drugs.com

• ClinicalTrials.gov – Studies Evaluating Daclatasvir
  https://clinicaltrials.gov

• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) – Hepatitis C Overview
  https://www.niddk.nih.gov

Prescription & documentation note

Daclaxen 60 mg Tablet is typically supplied against a valid prescription. For international orders, patients may need to provide documentation such as a licensed physician’s prescription, identification, and country-specific import documentation, depending on destination regulations. MedsMonk may assist with documentation guidance where applicable.